Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 2.41
-23 %
$ 119 M
Market Cap
-2.06
P/E
CASH FLOW STATEMENT
-50.9 M
OPERATING CASH FLOW
3.35 M
INVESTING CASH FLOW
56.8 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Akoya Biosciences, Inc.
| Net Income | -63.3 M |
| Depreciation & Amortization | 8.89 M |
| Capital Expenditures | -3.65 M |
| Stock-Based Compensation | 10.4 M |
| Change in Working Capital | -14.5 M |
| Others | 5.6 M |
| Free Cash Flow | -54.6 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (63.3) | (70.6) | (42.9) | (16.7) | (14.8) |
| Depreciation & Amortization | 8.9 | 7.1 | 4.8 | 3.8 | 3.1 |
| Deferred Income Tax | 51 K | 35 K | (0.2) | 7 K | 0.2 |
| Stock Based Compensation | 10.4 | 7.4 | 4.0 | 0.5 | 0.2 |
| Other Operating Activities | 7.6 | 0.4 | 2.8 | 3.2 | (1.0) |
| Change in Working Capital | (14.5) | 2.2 | (4.6) | 2.4 | (1.4) |
| Cash From Operations | (50.9) | (53.5) | (36.1) | (6.8) | (13.8) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (3.7) | (7.4) | (5.1) | (3.3) | (2.9) |
| Other Items | 7.0 | (6.7) | 0 | 10.0 | (10.0) |
| Cash From Investing Activities | 3.3 | (14.1) | (5.1) | 6.7 | (12.9) |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 10.6 | 30.6 | (0.3) | 9.8 | 5.0 |
| Dividends Paid | 0 | 0 | (1.4) | 0 | 0 |
| Other Financing Activities | (1.7) | (1.9) | 0.2 | (4.3) | 48.4 |
| Cash From Financing Activities | 56.8 | 28.7 | 137.0 | 5.5 | 28.6 |
| CHANGE IN CASH | |||||
| Net Change In Cash | 9.3 | (38.8) | 95.9 | 5.4 | 1.9 |
| FREE CASH FLOW | |||||
| Free Cash Flow | (54.6) | (60.9) | (41.2) | (10.1) | (16.6) |